Stem cell biology company Fate Therapeutics files for $69 million IPO – GeekWire
|
Stem cell biology company Fate Therapeutics files for $69 million IPO
GeekWire “Due to their natural ability to self-renew, and to regenerate and repair diseased or damaged tissue, adult stem cells hold considerable therapeutic promise,” the company writes in its SEC filing. “Based on our deep understanding of key biological … Fate Therapeutics, founded by stem cell experts, targets $69M IPOFierceBiotech Fate Therapeutics Joins Biotech IPO Conga Line, Reaching for $69MXconomy Fate …read more    |
